イスラジピン
(R)-4α-(ベンゾフラザン-4-イル)-1,4-ジヒドロ-2,6-ジメチル-3,5-ピリジンジカルボン酸3-イソプロピル5-メチル · イスロジピン · [R,(-)]-4-(ベンゾフラザン-4-イル)-1,4-ジヒドロ-2,6-ジメチル-3,5-ピリジンジカルボン酸3-メチル5-(1-メチルエチル) · 4-(2,1,3-ベンゾオキサジアゾール-4-イル)-1,4-ジヒドロ-2,6-ジメチルピリジン-3,5-ジカルボン酸3-イソプロピル5-メチル · イスラジピン · 4-(ベンゾフラザン-4-イル)-1,4-ジヒドロ-2,6-ジメチル-3,5-ピリジンジカルボン酸3-イソプロピル5-メチル · (4R)-4-(ベンゾフラザン-4-イル)-1,4-ジヒドロ-2,6-ジメチル-3,5-ピリジンジカルボン酸3-メチル5-(1-メチルエチル) · 4-(ベンゾフラザン-4-イル)-1,4-ジヒドロ-2,6-ジメチル-3,5-ピリジンジカルボン酸3-メチル5-イソプロピル
識別子と物理属性
| CAS No. | 75695-93-1 |
|---|---|
| 分子式 | C19H21N3O5 |
| 平均分子量 | 371.4 g/mol |
| 単同位体質量 | 371.14812078 g/mol |
| SMILES | COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12 |
| InChIKey | HMJIYCCIJYRONP-UHFFFAOYSA-N |
| PubChem CID | 3784 |
| ChEMBL | CHEMBL1648 |
| ChEBI | CHEBI:6073 |
| EC No. | 630-420-5 |
| DTXSID | DTXSID4023179 |
| 現地名 | イスラジピン |
化学・物理的性質
| XLogP | 4.3 |
|---|---|
| 極性表面積 | 104 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 8 |
| 回転可能結合数 | 6 |
| 重原子数 | 27 |
| 形式電荷 | 0 |
| 複雑度 | 685 |
| LogP（分配係数） | 4.282.901 |
| 溶解度 | Practically insoluble (< 10 mg/L at 37 °C)2.28e-01 g/LDMSO: ~26 mg/mL |
| 融点 | 168-170 °C168 - 170 °C166-1680C |
| Physical Description | Solid |
| Kovats Retention Index | 2578.89 |
| 沸点 | 501.9±60.0 °C(Predicted) |
| 密度 | 1.249±0.06 g/cm3(Predicted) |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | 2.56±0.70(Predicted) |
| 色 | 黄色 |
| Merck | 14,5240 |
| BCS Class | 2/4 |
| 安定性 | 購入日から2年間安定です。湿気を防ぎます。この DMSO またはエタノール溶液は、-20°C で 3 か月間保存できます。 |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3 |
| InChIKey | HMJIYCCIJYRONP-UHFFFAOYSA-N |
| SMILES | C1(C)NC(C)=C(C(OC(C)C)=O)C(C2C3C(C=CC=2)=NON=3)C=1C(OC)=O |
| CAS データベース | 75695-93-1(CAS DataBase Reference) |
| NISTの化学物質情報 | Isradipine(75695-93-1) |
化学的特性
Yellow Solid
安全性と法規制
| GHS 分類 | DangerH301 (98%): Toxic if swallowed [Danger Acute toxicity, oral]H319 (92.2%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H372 (92.2%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]H400 (98%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]H410 (98%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]P260, P264, P264+P265, P270, P273, P280, P301+P316, P305+P351+P338, P319, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 51 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (98%)Eye Irrit. 2 (92.2%)STOT RE 1 (92.2%)Aquatic Acute 1 (98%)Aquatic Chronic 1 (98%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)IsradipinevLess-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationBecause no information is available on the use of isradipine during breastfeeding, an alternate drug may be preferred.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
| 水環境危害等級（WGK） | 3 |
| 税関コード |
用途
説明
Isradipine is a long-acting calcium blocker effective in the treatment of essential hypertension. The advantages of isradipine as compared with other dihydropyridine calcium antagonists include a "gentle" onset and fewer contraindications. It can be taken by patients with diabetes mellitus, chronic obstructive airway diseases, gout, congestive heart failure or ischemic heart disease.
使用
Isradipine is a L-type calcium channel blocker, Isradipine has anti-atherosclerotic effects in animals and improves endothelium-mediated nitric oxide (NO)-dependent vasodilation in vitro. Additional studies indicate that Isradipine may provide a neuroprotective effect in a rat model of focal ischemia and that Isradipine produces a dose-dependent sparing of dopamine neuronal fibers and cell bodies.
一般的な説明
Isradipine, 4-(4-benzofuranazyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester (DynaCirc), is another second-generationdihydropyridine-type channel blocker. This drug, like theother second-generation analogs, is more selective for vascularsmooth muscle than for myocardial tissue. It is effectivein the treatment of stable angina, reducing the frequencyof anginal attacks and the need to use nitroglycerin.